Stem Cell Drug For Chronic Stroke - GXNPC1
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Stem Cell Drug For Chronic Stroke - GXNPC1
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Back to Hall of Fame
According to Taiwan Stroke Society, the rate of disability is 61.2% in poststroke patients after the first month of stroke and 55.58% after the sixth month of stroke. However, there are neither drugs nor treatments available for chronic stroke, thus the economic burden of long-term care is always a big concern for patients, family or country. In recent years, stem cell therapy and the field of regenerative medicine have provided new hope in the search for therapies against various diseases. Therefore, Gwo Xi develops the stem-cell drug for chronic stroke and provides new hope for stroke patients.
GXNPC1 stem-cell new drugs had confirmed its safety and efficacy in animal experiments. Also, it had completed phase I clinical trial (ClinicalTrials.gov Identifier: NCT02813512) in second quarter of 2018 and the result of data demonstrated the safety and preliminary efficacy. Further, it had passed the TFDA IND inspection and received the Phase II clinical trial permission (ClinicalTrials. gov Identifier: NCT04088149). In the future, we look forward to establishing the world’s first new stem cell drug for chronic stroke in Taiwan.
Highlights
Stem Cell New Drug for Chronic Stroke-GXNPC1 had confirmed its safety and efficacy in animal experiments and Phase I clinical trial (ClinicalTrials.gov Identifier: NCT02813512).
GXNPC1 had passed the TFDA IND inspection and received the Phase II clinical trial permission (ClinicalTrials.gov Identifier: NCT04088149).
GXNPC1 was also awarded the Innovative Product Awards in Taiwan and provides new hope for stroke patients.
View Website
Back to Hall of Fame
According to Taiwan Stroke Society, the rate of disability is 61.2% in poststroke patients after the first month of stroke and 55.58% after the sixth month of stroke. However, there are neither drugs nor treatments available for chronic stroke, thus the economic burden of long-term care is always a big concern for patients, family or country. In recent years, stem cell therapy and the field of regenerative medicine have provided new hope in the search for therapies against various diseases. Therefore, Gwo Xi develops the stem-cell drug for chronic stroke and provides new hope for stroke patients.
GXNPC1 stem-cell new drugs had confirmed its safety and efficacy in animal experiments. Also, it had completed phase I clinical trial (ClinicalTrials.gov Identifier: NCT02813512) in second quarter of 2018 and the result of data demonstrated the safety and preliminary efficacy. Further, it had passed the TFDA IND inspection and received the Phase II clinical trial permission (ClinicalTrials. gov Identifier: NCT04088149). In the future, we look forward to establishing the world’s first new stem cell drug for chronic stroke in Taiwan.
Highlights
Stem Cell New Drug for Chronic Stroke-GXNPC1 had confirmed its safety and efficacy in animal experiments and Phase I clinical trial (ClinicalTrials.gov Identifier: NCT02813512).
GXNPC1 had passed the TFDA IND inspection and received the Phase II clinical trial permission (ClinicalTrials.gov Identifier: NCT04088149).
GXNPC1 was also awarded the Innovative Product Awards in Taiwan and provides new hope for stroke patients.